China Construction Bank Corporation (601939.SS) vs Johnson & Johnson (JNJ)

China Construction Bank Corporation is one of China’s largest commercial banks, with a strong position in infrastructure finance, mortgages, corporate banking, deposits, payments, and wealth management. The bank serves households, government-linked entities, property developers, industrial companies, and small businesses. Its performance is shaped by Chinese loan demand, interest margins, deposit growth, asset quality, and public policy. Because of its scale, it is closely connected to China’s broader credit cycle and domestic economic conditions.

Johnson & Johnson is the world’s largest and most diversified healthcare company. Its operations are organized into two segments: Innovative Medicine and MedTech, which together account for all revenue following the 2023 separation of its consumer health business, Kenvue. After restructurings completed in 2023 and 2024, the pharmaceutical segment is focused on three core therapeutic areas: immunology, oncology, and neurology. From a geographic perspective, slightly more than half of the company’s total revenue comes from the United States.